DOP2011000185A - “COMPUESTO DE 5-(5-(2-(3-AMINOPROPOXI)-6-METOXIFENIL)-1H-PIRAZOL-3-ILAMINO)PIRAZIN-2-CARBONITRILO, AMINOPIRAZOL UTIL PARA INHIBIR LA PROTEINA CINASA Chk1” - Google Patents

“COMPUESTO DE 5-(5-(2-(3-AMINOPROPOXI)-6-METOXIFENIL)-1H-PIRAZOL-3-ILAMINO)PIRAZIN-2-CARBONITRILO, AMINOPIRAZOL UTIL PARA INHIBIR LA PROTEINA CINASA Chk1”

Info

Publication number
DOP2011000185A
DOP2011000185A DO2011000185A DO2011000185A DOP2011000185A DO P2011000185 A DOP2011000185 A DO P2011000185A DO 2011000185 A DO2011000185 A DO 2011000185A DO 2011000185 A DO2011000185 A DO 2011000185A DO P2011000185 A DOP2011000185 A DO P2011000185A
Authority
DO
Dominican Republic
Prior art keywords
cancer
useful
aminopropoxy
ylamino
carbonitrile
Prior art date
Application number
DO2011000185A
Other languages
English (en)
Inventor
Francine S Farouz
Ryan Coatsworth Holcomb
Ramesh Kasar
Steven Scott Myers
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DOP2011000185A publication Critical patent/DOP2011000185A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a un compuesto de 5-(5-(2-(3-aminopropoxi)-6-metoxifenil)-1H-pirazol-3-ilamino)pirazin-2-carbonitrilo,aminopirazol útil para inhibir la proteína cinasa Chk1 o una sal del mismo farmacéuticamente aceptable o un solvato de la sal, que inhibe la Chk1 y es útil en el tratamiento de cáncer, caracterizado porque el cáncer es seleccionado del grupo que consiste de cáncer de vejiga, cáncer de colon, cáncer gástrico, cáncer hepático, cáncer pulmonar, cáncer de mama, melanoma, cáncer de ovario, cáncer pancreático, mesotelioma, cáncer renal y cáncer uterino.
DO2011000185A 2008-12-17 2011-06-13 “COMPUESTO DE 5-(5-(2-(3-AMINOPROPOXI)-6-METOXIFENIL)-1H-PIRAZOL-3-ILAMINO)PIRAZIN-2-CARBONITRILO, AMINOPIRAZOL UTIL PARA INHIBIR LA PROTEINA CINASA Chk1” DOP2011000185A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13817608P 2008-12-17 2008-12-17

Publications (1)

Publication Number Publication Date
DOP2011000185A true DOP2011000185A (es) 2017-12-15

Family

ID=42079067

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2011000185A DOP2011000185A (es) 2008-12-17 2011-06-13 “COMPUESTO DE 5-(5-(2-(3-AMINOPROPOXI)-6-METOXIFENIL)-1H-PIRAZOL-3-ILAMINO)PIRAZIN-2-CARBONITRILO, AMINOPIRAZOL UTIL PARA INHIBIR LA PROTEINA CINASA Chk1”

Country Status (37)

Country Link
EP (1) EP2379532B1 (es)
JP (1) JP5705743B2 (es)
KR (1) KR101301777B1 (es)
CN (1) CN102245597B (es)
AR (1) AR074471A1 (es)
AU (1) AU2009333433B2 (es)
BR (1) BRPI0922468A2 (es)
CA (1) CA2746423C (es)
CL (1) CL2011001463A1 (es)
CO (1) CO6382122A2 (es)
CR (1) CR20110339A (es)
CY (1) CY1113930T1 (es)
DK (1) DK2379532T3 (es)
DO (1) DOP2011000185A (es)
EA (1) EA018118B1 (es)
EC (1) ECSP11011136A (es)
ES (1) ES2401558T3 (es)
HN (1) HN2011001446A (es)
HR (1) HRP20130167T1 (es)
IL (1) IL213160A (es)
JO (1) JO2886B1 (es)
MA (1) MA32901B1 (es)
MX (1) MX2011006603A (es)
MY (1) MY156998A (es)
NZ (1) NZ593440A (es)
PA (1) PA8850801A1 (es)
PE (1) PE20120077A1 (es)
PL (1) PL2379532T3 (es)
PT (1) PT2379532E (es)
RS (1) RS52739B (es)
SG (1) SG172222A1 (es)
SI (1) SI2379532T1 (es)
TN (1) TN2011000298A1 (es)
TW (1) TWI436996B (es)
UA (1) UA101998C2 (es)
WO (1) WO2010077758A1 (es)
ZA (1) ZA201103946B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314108B2 (en) * 2008-12-17 2012-11-20 Eli Lilly And Company 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts
JO3145B1 (ar) * 2010-11-08 2017-09-20 Lilly Co Eli مركبات مفيدة لتثبيط chk1
GB201402277D0 (en) 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds
TWI725041B (zh) * 2015-07-23 2021-04-21 美商美國禮來大藥廠 用於治療神經母細胞瘤及/或軟組織肉瘤之chk1/2抑制劑
AR106772A1 (es) * 2015-12-07 2018-02-14 Lilly Co Eli Sales de (s)-lactato
HK1254687A1 (zh) * 2015-12-15 2019-07-26 Eli Lilly And Company 用於癌症的联合疗法
HRP20220351T1 (hr) * 2016-02-04 2022-05-13 Pharmaengine, Inc. 3,5-disupstituirani pirazoli korisni kao inhibitori kinaze 1 kontrolne točke (chk1), i njihove pripreme i primjene
US20200108074A1 (en) 2017-03-31 2020-04-09 Seattle Genetics, Inc. Combinations of chk1- and wee1- inhibitors
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
CN112457306A (zh) 2019-09-06 2021-03-09 上海瑛派药业有限公司 3,5-二取代吡唑化合物作为激酶抑制剂及其应用
US11634424B2 (en) 2019-11-29 2023-04-25 Medshine Discovery Inc. Diazaindole derivative and use thereof as CHK1 inhibitor
WO2021119236A1 (en) 2019-12-10 2021-06-17 Seagen Inc. Preparation of a chk1 inhibitor compound
US11564920B2 (en) 2020-11-30 2023-01-31 Sumitomo Pharma Co., Ltd. 5-heteroaryl-1H-pyrazol-3-amine derivative
AU2021389190A1 (en) 2020-11-30 2023-06-29 Sumitomo Pharma Co., Ltd. 5-heteroaryl-1h-pyrazol-3-amine derivative
CA3219348A1 (en) 2021-05-27 2022-12-01 Anthony B. Pinkerton Checkpoint kinase 1 (chk1) inhibitors and uses thereof
GB202107924D0 (en) 2021-06-03 2021-07-21 Sentinel Oncology Ltd A pharmaceutical salt
GB202107932D0 (en) 2021-06-03 2021-07-21 Sentinel Oncology Ltd Preparation of a CHK1 Inhibitor Compound
US20250129049A1 (en) * 2021-12-24 2025-04-24 Sumitomo Pharma Co., Ltd. 1h-pyrazole-3-amine derivative having bicyclic backbone
US20250352541A1 (en) * 2022-05-27 2025-11-20 Sumitomo Pharma Co., Ltd. Therapeutic for cancer refractory to immune checkpoint inhibitor
JP7546104B2 (ja) * 2022-05-27 2024-09-05 住友ファーマ株式会社 ５－ヘテロアリール－１ｈ－ピラゾール－３－アミン誘導体からなる医薬
GB202213792D0 (en) 2022-09-21 2022-11-02 Benevolentai Bio Ltd New compounds and method
GB202403910D0 (en) 2024-03-19 2024-05-01 Benovental Cambridge Ltd New processes and intermediates for pharmaceutical products

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040034038A1 (en) 2002-08-13 2004-02-19 Goaquan Li Urea kinase inhibitors
MXPA06000933A (es) * 2003-07-25 2006-03-30 Pfizer Compuestos de aminopirazol y uso como inhibidores de chk1.
WO2008117050A1 (en) * 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
US20090270418A1 (en) * 2008-01-09 2009-10-29 Marianne Sloss Pyrazole pyrazine amine compounds as kinase inhibitors, compositions thereof and methods of treatment therewith

Also Published As

Publication number Publication date
PE20120077A1 (es) 2012-02-06
SI2379532T1 (sl) 2013-05-31
JP2012512249A (ja) 2012-05-31
HRP20130167T1 (hr) 2013-03-31
EP2379532A1 (en) 2011-10-26
CO6382122A2 (es) 2012-02-15
CR20110339A (es) 2011-09-14
IL213160A0 (en) 2011-07-31
AR074471A1 (es) 2011-01-19
MY156998A (en) 2016-04-15
UA101998C2 (ru) 2013-05-27
TWI436996B (zh) 2014-05-11
KR101301777B1 (ko) 2013-08-30
ZA201103946B (en) 2012-10-31
CN102245597A (zh) 2011-11-16
DK2379532T3 (da) 2013-03-18
IL213160A (en) 2013-12-31
JO2886B1 (en) 2015-03-15
CL2011001463A1 (es) 2012-01-20
CA2746423C (en) 2014-01-14
EP2379532B1 (en) 2013-02-20
AU2009333433B2 (en) 2012-06-14
WO2010077758A1 (en) 2010-07-08
CY1113930T1 (el) 2016-07-27
PT2379532E (pt) 2013-03-25
CN102245597B (zh) 2014-04-16
HK1160110A1 (en) 2012-08-10
ECSP11011136A (es) 2011-07-29
RS52739B (sr) 2013-08-30
EA201170834A1 (ru) 2011-12-30
MX2011006603A (es) 2011-09-27
JP5705743B2 (ja) 2015-04-22
PA8850801A1 (es) 2010-07-27
MA32901B1 (fr) 2011-12-01
EA018118B1 (ru) 2013-05-30
NZ593440A (en) 2013-02-22
TN2011000298A1 (en) 2012-12-17
AU2009333433A1 (en) 2011-06-30
HN2011001446A (es) 2013-08-05
BRPI0922468A2 (pt) 2020-08-04
KR20110084539A (ko) 2011-07-25
TW201029994A (en) 2010-08-16
PL2379532T3 (pl) 2013-07-31
CA2746423A1 (en) 2010-07-08
SG172222A1 (en) 2011-07-28
ES2401558T3 (es) 2013-04-22

Similar Documents

Publication Publication Date Title
DOP2011000185A (es) “COMPUESTO DE 5-(5-(2-(3-AMINOPROPOXI)-6-METOXIFENIL)-1H-PIRAZOL-3-ILAMINO)PIRAZIN-2-CARBONITRILO, AMINOPIRAZOL UTIL PARA INHIBIR LA PROTEINA CINASA Chk1”
MX2020010496A (es) Inhibidores de desmetilasa-1 especifica de lisina.
CY1120300T1 (el) Αντισωματα ειδικα στην κλαουδινη 6 (cldn6)
MX372766B (es) Anticuerpos que se unen a cldn6.
CL2013002430A1 (es) Compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de proteina kinasa trk; composicion farmaceutica; compuesto intermediarios; utiles para el tratamiento de carcinoma pailar de tiroides, cancer de pancreas, cancer de colon y carcinoma de mama, entre otras.
EA201891526A2 (ru) Ингибиторы лизин-специфической деметилазы-1
WO2008154249A3 (en) Gene expression markers of tumor resistance to her2 inhibitor treatment
MA52208A (fr) Biomarqueurs pour une maladie du greffon contre l'hôte
MX378499B (es) Compuestos antifungicos.
HK1243326A1 (zh) 溴结构域抑制剂
MA40074A (fr) Composés liant ras multivalents
SA519410025B1 (ar) مثبطات ديميثيلاز-1 نوعي لللايسين
PH12017500881A1 (en) Aurora a kinase inhibitor
HK1210611A1 (en) Histone demethylase inhibitors
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
MX2016008624A (es) Inhibidores de serina/treonina cinasa.
HN2009000455A (es) Inhibidore de quinasa
CL2008003200A1 (es) Compuestos derivados de tiazol, inhibidores de la proteina quinasas; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de vejiga, de mama y de rinon.
ZA201000085B (en) 2-oxo-3-benzyl-benzoxazol-2-one derivatives and related compounds as Met kinase inhibitors for the treatment of tumors
EA201790502A1 (ru) Ингибиторы гистоновых диметилаз
IN2014MN02107A (es)
HRP20150530T1 (hr) Spojevi korisni za inhibiranje chk1
EA200870426A1 (ru) Производные тиазолидиндиона в качестве ингибиторов pi3 киназы
EA201891578A1 (ru) Композиции 2-(4-хлорфенил)-n-((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-5-ил)метил-2,2-дифторацетамида
MX2018008507A (es) Inhibición de proteína relacionada con ataxia telangiectasia y rad3 (atr).